DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20162485

Cost analysis of antiepileptic drugs available in India

Ajay Kumar Shukla, Rekha Mehani

Abstract


Background: Epilepsy is one of the major causes of morbidity, mortality and needs long-term treatment. There is a wide range of variation in the prices of drugs marketed in India. Thus, a study was planned to analyse out cost variations of antiepileptic drugs available in Indian market.

Methods: Minimum and maximum costs in rupees (INR) of antiepileptic agents manufactured by different companies, in the same strength and dosage forms were obtained from “current index of medical specialties” January ‑ April 2016. The cost ratio and percentage cost variation were calculated for each generic antiepileptic agent.

Results: There is a wide variation in the prices of different brands of same antiepileptic agent in Indian market. The highest cost ratio and percent cost variation was found for divalproex 500 mg [(1:3.17) and 216.7], followed by lamotrigine 25 mg [(1:2.5) and 150], clobazam 10 mg [(1:2.47) and 147.3] and clonazepam 0.5 mg [(1:2.46) and 145.9].

Conclusions: The average percentage price variation of different brands of the same oral antiepileptic drugs in Indian market is very wide. Treatment of epilepsy has a long course with compliance being a key factor for successful treatment. Improved adherence to the treatment can be ensured by decreasing the cost of therapy, by changes in the government policies and regulations and creating awareness among treating physicians for switching to cost effective therapy.


Keywords


Cost analysis, Compliance, Adherence, Epilepsy, Health Economics, Cost variation

Full Text:

PDF

References


Santhosh NS, Sinha S, Satishchandra P. Epilepsy: Indian perspective. Annals of Indian Academy of Neurology. 2014;17(Suppl 1):S3-S11.

Sridharan R, Murthy BN. Prevalence and pattern of epilepsy in India. Epilepsia.1999;40:631-6.

Lowenstein DH. Seizures and Epilepsy. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 19th ed. New York, NY: McGraw-Hill; 2015:2542-2559.

McNamara JO. Pharmacotherapy of the epilepsies. In: Brunton LB, Chabner BA, Knollman BC, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics.12th ed. New York, NY: McGraw-Hill; 2011:583-606.

Porter RJ, Meldrum BS. Antiseizure drugs. In: Katzung BC, Trevor AJ. Basic and Clinical Pharmacology.13th ed. New York, NY: McGraw-Hill; 2015:566.

Boylan L, Gagne J. Nonequivalence of equivalence methods. Ann Neurol. 2012;71(2):284-5.

Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160‑3.

Pharmacoeconomics: Principles, Methods, and Applications. DiPiro JT, Lamber RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a Pathophysiologic Approach. 19th e. New York, NY: McGraw-Hill; 2011:01.

Gupta SK. Proposed pharmacoeconomics guidelines for India (PEG-I). IPSOR India Chapter; 2013:79-100.

Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med. 2007;4(9):e283.

Jana S, Mondal P. Pharmacoeconomics: the need to sensitize undergraduate medical students. Indian J Pharmacol. 2005;37(5):277-8.

Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332-7.

Akila L, Rani RJ. Cost analysis of different brands of antianginal drugs available in India. Int J Basic Clin Pharmacol. 2015;4:860-3.

Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028-35.

Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among medicare beneficiaries. Health Affairs. 2003;22(4):220-9.

Garnett WR. Antiepileptic drug treatment: outcomes and adherence. Pharmacotherapy. 2000;20:191S-199S.

Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes: a literature review. Pharmacy and Therapeutics. 2012;37(1):45-55.

Gagne JJ, Kesselheim AS, Choudhry NK, Polinski JM, Hutchins D, Matlin OS, et al. Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy Behav. 2015;52(Pt A):14-8.

Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol. 2011;43:131-6.

World Health Organisation. Essential drugs and medicines: Drug finance. Available at http://www.whoindia.org/EN/Section2/Section/Section160_959.html. Accessed 12 September 2014.

Creese A, Kotwani A, Kutzin J, Pillay A. Evauating pharmaceuticals for health policy in low and middle income country settings. In: Freemantle N, Hill S, editors. Evaluating pharmaceuticals for health policy and reimbursement. Massachusetts, USA: Blackwell Publication; (in collaboration with WHO Geneva); 2004:227-43.

Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med. 1991;115(2):116-21.